ArticleFrontiers in microbiology2022
A Shift in Perspective: A Role for the Type I Toxin TisB as Persistence-Stabilizing Factor.
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Antimicrobial Armageddon: The Professional Guide to Conquering Antibiotic Resistance.Probiotics and antimicrobial proteins · 2026Article
- An RNA structural switch controlling bacterial toxin translation.Nucleic acids research · 2026Article
- Combinations of colistin and bacteriocins prevent the selection of colistin resistance in Acinetobacter baumannii.Communications biology · 2026Article
- Less missing values-evaluation of proteomics workflows for the quantification of (small) proteins.microLife · 2026Article
- Bistability in type I toxin-antitoxin systems may lead to stress-induced persister formation.NPJ systems biology and applications · 2025Article
- Toxin-antitoxins and sigma factors may optimize the fitness of free-living bacteria throughout the life cycle via an integrated nutrient-responsive cybernetic system.Journal of the Royal Society, Interface · 2025Review
- Membrane selectivity and pore formation of SprA1 and SprA2 hemolytic peptides from Staphylococcus aureus type I toxin-antitoxin systems.The FEBS journal · 2025Article
- Functional diversity and molecular interactions of small membrane proteins in bacteria.microLife · 2025Review
- Type I toxin-antitoxin systems in bacteria: from regulation to biological functions.EcoSal Plus · 2024Review
- Article
- Large Roles of Small Proteins.Annual review of microbiology · 2024Review
- Proton motive force and antibiotic tolerance in bacteria.Microbial biotechnology · 2024Review
- TisB protein is the single molecular determinant underlying multiple downstream effects of ofloxacin inScience advances · 2024Article
- Transcriptomic analysis using RNA sequencing and phenotypic analysis ofFrontiers in microbiology · 2024Article
- Review
- Variability in Adaptive Resistance ofAntibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial persistence is a phenomenon that is founded by the existence of a subpopulation of multidrug-tolerant cells. These so-called persister cells endure otherwise lethal stress situations and enable restoration of bacterial populations upon return to favorable conditions. Persisters are especially notorious for their ability to survive antibiotic treatments without conventional resistance genes and to cause infection relapse. The persister state is typically correlated with reduction or inhibition of cellular activity. Early on, chromosomal toxin-antitoxin (TA) systems were suspected to induce the persister state in response to environmental stress. However, this idea has been challenged during the last years. Especially the involvement of toxins from type II TA systems in persister formation is put into question. For toxins from type I TA systems the debate has just started. Here, we would like to summarize recent knowledge gained for the type I TA system
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.